DXR
Daxor Corporation
Set alert
9.20 USD +0.28 +3.14%
8.40 Day range 9.20
8.87 52-week range 14.75
- YTD
- -37.63%
- 1 year
- -31.19%
- Open
- 8.86
- Prev close
- 8.92
- Mkt cap
- 53.71M
- Vol
- 28.01K
- Avg vol
- 19.56K
- EPS
- 1.10
- P/E
- 8.36
- Div yield
- 0.00%
More statistics
- Low
- 8.40
- High
- 9.20
- Forward P/E
- 0.00
- Beta
- -0.54
- Short ratio
- 0.60
- Inst. own
- 1.94%
- Dividend
- 0.00
- Ex-div date
- Jan 4, 2018
- Earnings
- Mar 28, 2012
- 50-d avg
- 8.96
- 200-d avg
- 9.04
- 1y target
- 23.38
Key statistics
- Market cap
- 40.17M
- Enterprise value
- 0
- Trailing P/E
- 7.16
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 260.51
- Price / book
- 1.23
- EPS (TTM)
- 1.16
- Beta
- -0.54
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 1094.00%
- Revenue (TTM)
- 154.21K
- Revenue growth
- -11.40%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 1.65M
- Return on equity
- 5.35%
- Shares outstanding
- 4.84M
- Short % of float
- 0.71%
- 50-day average
- 8.96
- 200-day average
- 9.04
Analyst view
Consensus: none
Price target (mean) 23.38 +154.1% upside
Now 9.20
- Target (low)
- 22.00
- Target (mean)
- 23.38
- Target (high)
- 24.75
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 28, 2012
Expected Mar 28, 2012. Consensus EPS estimate 0.00.
Financials — quick view
DXR Revenue — quarterly 369.83K
DXR Net income — quarterly -1.49M
DXR EPS — quarterly -0.36
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 28, 2012 | Dec 1, 2011 | 0.00 | — | — | — |
| Nov 14, 2011 | Sep 1, 2011 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 2024 | Ascendiant Capital | main | Buy | Buy |
| Jul 29, 2019 | Maxim Group | init | — | Buy |
| May 16, 2019 | Ascendiant Capital | init | — | Buy |
About Daxor Corporation
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- daxor.com
News
- Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26
- Daxor Announces New Clinical Studies Validate BVA Technology In High-Acuity Heart Failure Populations To Enhance Care At HFSA 2026 Annual Scientific Meeting
- Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026
- Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026
- Daxor Corporation (NASDAQ:DXR) Sees Large Growth in Short Interest
- Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026
- Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
- Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
- Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas
- Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas
Your note
Sign in to keep a note on DXR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FELDSCHUH JONATHAN ADAM | Officer and Director | Purchase | Dec 5, 2024 | 35,908 |
| FELDSCHUH MICHAEL RICHARD | Chief Executive Officer | Purchase | Dec 5, 2024 | 207,492 |
| FEUER EDWARD | Director | Purchase | Mar 3, 2024 | 1,000 |
| GOUDIE JOY S | Director | Purchase | May 23, 2023 | 300 |
| JOSEPH FELDSCHUH UEO | Trustee | Stock Gift | Sep 17, 2023 | 2,549,460 |
| MICHEL ROBERT J | Chief Financial Officer | Purchase | Mar 26, 2024 | 11,300 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.01% | 48,828 | 405.27K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.31% | 14,821 | 123.01K | Sep 29, 2024 |
| Keyes, Stange & Wooten Wealth Management, LLC | 0.30% | 14,612 | 121.28K | Sep 29, 2024 |
| Osaic Holdings Inc | 0.15% | 7,200 | 59.76K | Sep 29, 2024 |
| UBS Group AG | 0.03% | 1,236 | 10.26K | Sep 29, 2024 |
| Princeton Global Asset Management LLC | 0.01% | 500 | 4.15K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.01% | 48,828 | 405.27K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.13% | 6,305 | 52.33K | Sep 29, 2024 |
| Gabelli Global Mini Mites Fund | 0.01% | 400 | 3.32K | Sep 29, 2024 |
| Northern Small Cap Core Fund | 0.00% | 37 | 307 | Sep 29, 2024 |